Seeking Alpha

Eli Lilly (LLY -0.6%) stops developing its Tabalumab drug to treat rheumatoid arthritis almost...

Eli Lilly (LLY -0.6%) stops developing its Tabalumab drug to treat rheumatoid arthritis almost two months after data from a Phase III study demonstrated that the medicine would probably not be effective. However, Lilly will continue late-stage testing of Tabalumab in patients with an auto-immune disorder called systemic lupus erythematosus, and Phase II trials for multiple myeloma. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|